Dentists in Paoli, IN Accepting Medicare
5 Dentists found. Showing 1 - 5
 Dr. Herbert Ray Stevens, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1326 W Leonard Circle, Paoli, IN 47454 Phone: 812-723-2130 Fax: 812-723-2130 |
Dr. Andrew Stephen Becht, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1570 W Hospital Rd, Paoli, IN 47454 Phone: 812-723-3959 |
Dr. George R Bell, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 138 S Court St, Paoli, IN 47454 Phone: 812-723-3800 |
Michael K Vanemon, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1570 W Hospital Rd, Paoli, IN 47454 Phone: 812-723-3959 Fax: 812-723-3909 |
Dr. Scott Michael Lewis, DMD Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 488 W Hospital Rd, Paoli, IN 47454 Phone: 812-723-3959 |
News Archive
FDA-approved drug for lymphoma and leukemia may help treat common type of brain tumor
New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug for lymphoma and leukemia, may also help treat the most common – and deadliest – type of brain tumor.
Multaq approved for atrial fibrillation by FDA
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Study finds link between long-term exposure to childhood poverty and obesity rates among young adults
A new study from the University of Houston Department of Health and Human Performance finds childhood poverty reaches into the lives of white, Hispanic and African-American young adult women, contributing to their propensity to be overweight and obese.
Urigen Pharmaceuticals secures debt held by Platinum-Montaur Life Sciences
Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the secured debt held by Platinum-Montaur Life Sciences, LLC has been converted into a newly created Series C Preferred Stock of the Company. As a result of the conversion, the lien on the Company's assets, including its intellectual property will be extinguished.
Improvements in pharmacological study to fight cognitive impairment in schizophrenia
A study by the UPV/EHU has assessed the effectiveness of various drugs, which are used to delay cognitive deterioration in patients with Alzheimer's, in improving cognitive impairment displayed by patients with schizophrenia.
› Verified 2 days ago
Pharmacists
Clinical Social Workers
Occupational Therapists
Dentists
Counselors
Psychologists